Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Wraps Up Its Reorganization; 60 Staffers Cut, R&D Shops Shut

NEW YORK, Feb. 25 (GenomeWeb News) - Transgenomic yesterday said it has wrapped up a previously announced restructuring that resulted in 60 job cuts and the closure of R&D facilities related to its nucleic acids segment.

 

As part of the reorganization, which also saw the closure of two European field offices, Transgenomic will record approximately $3.5 million in fourth-quarter 2004 costs.

 

As GenomeWeb News reported in November 2004, Transgenomic disclosed plans to shutter a facility in Boulder, Colo., and lay off 60 staffers as part of a broader effort to trim costs.

 

At the time, the Omaha, Neb.-based company said it sold its oligonucleotide-manufacturing facility and downsized as it continues to struggle to trim expenses and save cash. Transgenomic announced the belt-tightening as part of its third-quarter 2004 financial report, in which a mild up-tick in revenue amid widening losses and slightly more than $1 million in the bank painted a bleak near-term picture for the company.

 

Transgenomic had also said it would lay off around 60 employees worldwide, and close two US-based research and development facilities linked to the firm's synthetic nucleic acid business, and two European field offices.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.